OR WAIT 15 SECS
Witnessing an industry's wild ride is perhaps the best reason to work for a business magazine. You've given us 25 years of excitement. And we plan to pay you back.
Following an industry's wild ride is one of the great pleasures of being a trade journalist. From that perspective, I could hardly ask for a better subject matter than pharma. Here at Pharm Exec, we've been spending a lot of time thinking about the industry and its recent past, as we prepare for our year-long celebration of our 25th anniversary. (I don't want to spoil all the surprises just yet, but we think you'll enjoy and benefit from the events and editorial projects we have in the works.) As we look over the pharma-related events that have taken place since the magazine launched in January of 1981, it's hard not to be left gasping. Here's just a tiny sample:
I could go on and on. The point is clear, though. This has been an amazing quarter century for pharma, and it has brought us to a point at which the next quarter century can only be more of the same. New markets will emerge in India, China, and Latin America. New techniques—especially nanotechnology and gene therapy—will come of age. The industry will weather the coming years of belt tightening and become something different and, one hopes, stronger. A lot of political football will be played, and who knows, at some point, maybe some other industry will replace pharma as ball.
It should be an exciting ride, not necessarily fun, but important not just for the industry but for patients as well. I know you're on board, and your friends here at Pharm Exec are as well. We've always tried to bring you the tools and ideas you need to survive and thrive on the roller coaster that is pharma. For our next 25 years, we promise to look harder, probe deeper, think more expansively, and bring you more value. Happy birthday from us.